- Summary
- Price Reports
- Price History
- Add To Your Stocklist
- View your Stocklist
- Basic Chart
- Interactive Chart
- Headlines
- Company Snapshot
- Summary Reports
- Free Annual Report
- Estimate Snapshot
- Estimate Report
- Mobile Quote
- Real-Time Quote
- Streaming Quote
|
Javelin Pharmaceuticals | Company Snapshot
-
![]()
-
-
-
Vol:
-
Last Trade:
|
JAVELIN PHARMACEUTICALS INC.
JAVELIN PHARMACEUTICALS INC., is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs & improved formulations of existing drugs that target current unmet & underserved medical need in the pain management market. Javelin’s product candidates address the acute moderate-to-severe pain medication market segment. They are developing differentiated pain control products that provide the flexibility & versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Indications under development include post-operative pain, orthopedic injury pain, procedural pain, burn pain & trauma. Our product candidates offer enhanced pain relief, fewer adverse side effects & faster relief of pain compared to other currently available treatments. Javelin has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) & PMI-150 (intranasal ketamine).
|
|
| Symbol: |
JAV |
| Exchange(s): |
American Stock Exchange |
| Industry: |
Consumer Products (Biotechnology & Pharmaceuticals) |
| 5-Star Rating: |
 |
|
ANNUAL FINANCIALS
|
|
|
Dec 31, 2008
12 Months
us$
|
Dec 31, 2007
12 Months
us$
|
Dec 31, 2006
12 Months
us$
|
3Yr.
Growth
% Change
|
|
Total Revenue ($000)
|
1,100
|
0
|
840
|
-10.61
|
|
Earnings before Interest & Tax ($000)
|
-43,440
|
-31,030
|
-17,790
|
N/A
|
|
Profit/Loss ($000)
|
-43,460
|
-31,030
|
-17,790
|
N/A
|
|
Earnings per Share
|
-0.77
|
-0.68
|
-0.44
|
N/A
|
|
Total Assets ($000)
|
29,300
|
43,150
|
21,440
|
-5.24
|
|
Dividends Per Share
|
0.00
|
0.00
|
0.00
|
|
|
Return on Com. Equity
|
-157.52
|
-117.67
|
-69.18
|
|
|
Employees
|
N/A
|
N/A
|
N/A
|
|
|
|
|
|
Trailing 12 Month Results
|
|
|
12 Months ended
Dec 31, 2009,us$
|
12 Months ended
Dec 31, 2008,us$
|
%Change
|
|
Total Revenue ($000)
|
N/A
|
1,110
|
N/A
|
|
Profit/Loss ($000)
|
N/A
|
-43,440
|
N/A
|
|
Earnings per Share
|
N/A
|
-0.77
|
N/A
|
|
Dividends Per Share
|
0.00
|
0.00
|
|
Number of Shares
|
63,880,000
|
60,620,000
|
|
|
|
|
|
COMPANY INFORMATION
|
| Key Personnel |
| CEO: Daniel B. Carr, Vice-Chmn. Dir. |
| CFO: Fred H. Mermelstein, Pres.; Dir. |
| |
| Contact Information |
| Address: |
125 CambridgePark Drive,
Cambridge,
MA,
02140 |
Phone: |
617-349-4500 |
| Fax: |
617-349-4505 |
| Web Address: |
www.javelinpharmaceuticals.com |
| E-Mail : |
info@javelinpharma.com |
| |
| Incorporation:
| United States |
| |
|
Securities:
|
JAV-A
|
|
| |
|
|
| |
|
|
Financial data is provided by Zacks Investment Research.
| |
All information on this site is compiled by CTVglobemedia Publishing Inc. from reliable industry sources. While all efforts are made to ensure the accuracy of the information, CTVglobemedia Publishing Inc. and its related entities assume no liability for incorrect, incomplete, or missing information from this site. Past performance is not necessarily indicative of future performance. Prior to making any investment decision, consult with a qualified investment advisor.
Copyright © 2010 CTVglobemedia Publishing Inc. All rights reserved.
|
|
|
